J&J Vaccine Booster in Transplant Recipients


About this study

The purpose of this study is to determine if “booster” revaccination with the Janssen Ad26.CoV2.S vaccine (JNJ-78436735, aka the J&J vaccine, a viral vector vaccine) increases anti-COVID spike protein antibody levels in solid organ transplant recipients who did not form acceptable levels of anti-COVID spike protein antibody after receiving two doses of a mRNA vaccine: Pfizer-BioNTech (BNT162b2 vaccine) or Modena (mRNA-1273). 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Criteria for Entry into the Study:

- Any kidney transplant recipient from Mayo Clinic who has received the mRNA vaccine
(two or three dose mRNA vaccine-Moderna or Pfizer) and are >28 days after most recent
vaccination at the time of spike protein assessment.

- Recipients of a kidney transplant, including those transplanted with other solid organ
transplants in addition to the kidney. Subjects may have received more than 1 kidney

- More than 90 days since any transplant including a kidney transplantation. ?≥18 years
of age on the day of consent.

Criteria for Entry into Segment I

- Must have a Roche Elecsys® Anti-SARS-CoV-2 S level of <250 U/mL to be eligible for
Segment I.

- Platelet count of >75,000/µL on the day of vaccination with the Janssen Ad26.CoV2.S

- Contraceptive (birth control) use should be consistent with local regulations
regarding the acceptable methods of contraception for those participating in clinical

- Before randomization, participants must be either:

- Not be of childbearing potential

- Of childbearing potential and practicing an acceptable effective method of
contraception. Subject must agree to remain on contraception from date of consent
until 3 months after the last dose of the Janssen Ad26.CoV2.S vaccine. Use of
hormonal contraception should start at least 28 days before the 1st
administration of the Janssen Ad26.CoV2.S vaccine. The sponsor-investigator
should evaluate the potential for contraceptive method failure (for example,
noncompliance, recently initiated) in relationship to the Janssen vaccination.
Acceptable effective method a for this study include:

- Hormonal contraception:

- Combined (estrogen and progestogen containing) hormonal contraception associated with
inhibition of ovulation (oral, intravaginal, or transdermal)

- Progestogen-only hormonal contraception associated with inhibition of ovulation (oral,
injectable, or implantable)

- Intrauterine device

- Intrauterine hormone-releasing system

- Bilateral tubal occlusion/ligation procedure

- Vasectomized partner (the vasectomized partner should be the sole partner for
that participant)

- Sexual abstinence (defined as refraining from heterosexual intercourse from the
date of consent until 3 months after the last dose of the Janssen Ad26.CoV2.S
vaccine. The reliability of sexual abstinence needs to be evaluated in relation
to the duration of the study and the preferred and usual lifestyle of the
participant.). Note: Use of condoms is not considered as an acceptable
contraceptive barrier method due to the failure rate of female and male condoms
(Centers for Disease Control and Prevention. Reproductive Health: Contraception.
https://www.cdc.gov/reproductivehealth/contraception/index.htm. Accessed 23
November 2020)

- If subject is female and of childbearing potential, she must:

- Have a negative highly sensitive serum pregnancy test prior to vaccination.

- Participant agrees to not donate bone marrow, blood, and blood products from the first
Janssen Ad26.CoV2.S vaccine administration until 3 months after the last dose of the
Janssen Ad26.CoV2.S vaccine.

Exclusion Criteria:

- Clinically significant acute illness (this does not include minor illnesses such as
diarrhea or mild upper respiratory tract infection) or temperature ≥38.0ºCelsius (C)
(100.4°Fahrenheit [F]) within 24 hours prior to the planned 1st dose of the Janssen
Ad26.CoV2.S vaccine; randomization at a later date is permitted at the discretion of
the sponsor-investigator.

- Has a known or suspected allergy or history of anaphylaxis or other serious adverse
reactions to vaccines or their excipients (including specifically the excipients of
the Janssen Ad26.CoV2.S vaccine; refer to the Investigative Brochure).

- Subject has received or plans to receive:

- Licensed live attenuated vaccines -within 28 days before or after planned
administration of the 1st or subsequent Janssen vaccinations.

- Other licensed (not live) vaccines -within 14 days before or after planned
administration of the 1st or subsequent Janssen vaccinations.

- Received an investigational drug within 30 days (including investigational drugs for
prophylaxis of COVID-19) or used an invasive investigational medical device within 30
days of the Janssen Ad26.CoV2.S vaccine. Received investigational Ig or
investigational monoclonal antibodies within 3 months, or received convalescent serum
for COVID-19 treatment within 4 months or received an investigational vaccine
(including investigational Adenoviral- vectored vaccines) within 6 months before the
planned administration of the 1st dose of the Janssen Ad26.CoV2.S vaccine or is
currently enrolled or plans to participate in another investigational study within 3
months after the last Jansen vaccination.

Note: Participation in an observational clinical study is allowed at the
sponsor-investigator's discretion; please notify the sponsor-investigator of this decision.
Efforts will be made to ensure inclusion of participants who have not been previously
enrolled in coronavirus studies. In order to participate subject must agree and understand
that they cannot enroll in other coronavirus focused studies while participating in this

- Is pregnant or planning to become pregnant at the time of consent and within 3 months
of the last dose of the Janssen Ad26.CoV2.S vaccine.

- Has a history of an underlying clinically significant acute or chronic medical
condition or physical examination findings which, in the opinion of the
sponsor-investigator, would make study participation not be in the participant's best
interest (e.g., compromise the well- being) or that could prevent, limit, or confound
the protocol-specified assessments.

- Has a contraindication to Intramuscular (IM) injections and blood draws.

- Has had major psychiatric illness, which in the sponsor-investigator's opinion would
compromise the participant's safety or compliance with the study procedures.

- Cannot communicate reliably with the sponsor-investigator or comply with study

- In the opinion of the sponsor-investigator, is unlikely to adhere to the requirements
of the study or is unlikely to complete the full course of protocol required
vaccination and observation.

- History of cancer malignancy within 1 year before screening (exceptions are squamous
and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or other
malignancies with minimal risk of recurrence).

- History of acute polyneuropathy (e.g., Guillain-Barré syndrome)

- Chronic history of platelet count <75,000/µL.

- History of thrombosis with thrombocytopenia syndrome (TTS) or heparin-induced
thrombocytopenia (HIS).

- History of capillary leak syndrome (CLS).

- Received pre-exposure prophylactic medications for COVID-19 that could interfere with
assessments of any study-related endpoint

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/20/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Open for enrollment

Contact information:

Maria Xiong

(507) 293-5772


Jacksonville, Fla.

Mayo Clinic principal investigator

Hani Wadei, M.D.

Open for enrollment

Contact information:

Clinical Studies Unit

(904) 953-2255

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Sumi Nair, M.B.B.S., M.D.

Open for enrollment

Contact information:

Angela Mathews

(480) 342-3988


More information


Publications are currently not available